Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.06.11.659156

Panel Perils: How Size, Fluorochrome Choices, and Unmixing Algorithms Shape Your Analysis Adventure!

Abstract

IntroductionThe advent of full spectral flow cytometry has enabled the development of complex panels with over 35 colors, with the latest panels reaching 50 colors (1). This capability is made possible by cytometers equipped with numerous detectors beyond those in traditional cytometers and an expanded range of fluorochromes with emission peaks across the visible spectrum. However, our observations reveal significant challenges in the current unmixing, spread prediction, and panel design methodologies. Existing tools and guidelines, largely optimized for panels with up to 20+ colors, are limited in their ability to navigate this new ultra-high-color landscape. Without improvements in unmixing algorithms, predictive tools for spread, and design strategies, researchers risk creating suboptimal panels and obtaining inaccurate results. This article aims to highlight a range of emerging challenges associated with ultra-high parameter flow cytometry, particularly for practitioners accustomed to conventional panel design and analysis. As the field advances toward increasingly complex multiparameter experiments, novel issues have surfaced--many of which were previously unrecognized. Although this work does not provide comprehensive solutions to all of these observations, it underscores the need for continued methodological development. We anticipate that ongoing research by experts in the field will yield robust frameworks to address these challenges and advance best practices in high-dimensional cytometric analysis. Brief descriptionO_LIDifferent unmixing/compensation algorithms can result in different biological interpretations from the same raw dataset. C_LIO_LIA method to identify the optimal unmixing algorithm for accurate analysis is discussed. C_LIO_LIBoth panel size and specific fluorochrome combinations significantly impact population spread. C_LIO_LISSM (Spillover Spreading Matrix) values are influenced by panel size and fluorochrome combinations, which, if not carefully evaluated, may lead to misleading conclusions during panel design. C_LI

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Bhowmick, D., Bushnell, T.. 2025-06-17. Panel Perils: How Size, Fluorochrome Choices, and Unmixing Algorithms Shape Your Analysis Adventure!. https://doi.org/10.1101/2025.06.11.659156

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Sequence context and partner availability specify divergent cell fates from a single transcription factor

Transcription factors drive the gene regulatory networks that control developmental transitions, yet which of their many targets a cell uses remains unresolved. Expressing Cebp, Cebp{beta} or Cebp{delta} identically, alone or with Oct4, Sox2, Klf4 and cMyc, gave four outcomes: adipocyte from fibroblasts and neural stem cells, trophectoderm from embryonic stem cells, and myeloid from B cells. Raising Cebp levels changed how many sites it reached, not which sequence it read: clustered motifs maintained somatic enhancers, while spillover onto low-copy sites created de novo enhancers carrying composites of Cebp and cell-type-restricted partners. In fibroblasts, Cebp also redistributed Oct4, Sox2 and Klf4 from early targets, blocking iPSC formation. Supplying the predicted partners rewrote the output: Spi1 redirected Cebp into parallel adipogenic and myeloid programs, via a transient PpargCD45 state using separate enhancers for each; TFAP2C abolished adipogenic conversion. Motif density and partner composites therefore assemble a factor's instructive output in the receiving cell.

cell biology↗

Tracking the conformational dynamics of single molecules in live cells; GTPase cycling in Cdc42 gradients and microclusters

The Rho family of GTPases play a critical role in many cellular processes by acting as molecular switches relying on conformational changes to transition between active and inactive states. The spatial distribution and kinetics of these conformational changes are complex and vary across the cell. We describe here biosensors based on environment-responsive fluorescent dyes, capable of reporting the conformational changes of individual GTPase molecules as they traffic within living cells (SPARC Cdc42 and SPARC Rac1, 'Single Particle Activation Reporter Constructs'). We use SPARC Cdc42 to determine the rates of different steps in GTPase regulation, activation/inactivation and membrane insertion, that together generate localized gradients of Cdc42 activity driving cell motility. The biosensors also revealed heterogeneously distributed clusters of Cdc42, the mechanisms of their activation, and potential roles in polarized motility.

cell biology↗

High-content screening identifies FDA-approved activators of mitophagy

Mitochondrial diseases are highly heterogeneous disorders caused by defects in oxidative phosphorylation, for which only limited therapeutic options are available. The elimination of dysfunctional mitochondria via mitophagy activation is an attractive strategy to treat several mitochondrial diseases, irrespective of the underlying genetic defect. To identify pharmacological activators of this pathway, we performed a high-content screening of 1,971 FDA-approved compounds using cellular reporters of TFEB nuclear translocation and mitophagy. This screening identified 294 compounds that promoted TFEB translocation, nine of which increased the number of mitolysosomes without compromising cell viability or damaging mitochondria. Among the selected compounds, Meptazinol and Ponatinib emerged as the top-ranked mitophagy inducers in fibroblasts from patients with complex I and IV deficiency, respectively, and were prioritised for further characterisation. However, they did not rescue the bioenergetic defect, suggesting that the stimulation of mitophagy per se is not sufficient to ameliorate the OXPHOS defect in mitochondrial diseases. Overall, our findings establish a scalable platform for the identification of pharmacological activators of TFEB and identify candidate compounds for therapeutic modulation of mitophagy.

cell biology↗